

Supplementary Table 1. Clinical findings for each tumor type in the training set

		HP n=8	SSL n=25	SSLD/SSL with EIC n=10	TSA n=28	Low grade adenoma n=17	High grade adenoma n=14	HGD n=16	EIC n=8
Age (y, mean ± SD)		63.9 ± 14.2	64.6 ± 10.6	66.1 ± 13.1	65.0 ± 13.2	72.5 ± 7.9	64.3 ± 12.5	65.9 ± 14.5	63.4 ± 12.7
Gender	Female	1	16	6	10	4	3	5	2
	Male	7	9	4	18	13	11	11	6
Location	Proximal	5	24	8	4	10	1	6	4
	Distal	3	1	2	24	7	13	10	4
Size (mm, mean ± SD)		6.4 ± 1.9	11.8 ± 3.8	12.7 ± 3.6	11.4 ± 7.0	5.2 ± 1.8	12.9 ± 4.2	14.3 ± 3.7	19.0 ± 10.8
Morphology	Depressed	0	0	0	0	0	0	0	4
	Flat	4	23	2	0	12	2	0	3
	Flat plus protoruding	1	1	8	12	0	1	2	0
	Protoruding	3	1	0	16	5	11	14	1

SSLD, SSL with dysplasia; HGD, high grade dysplasia, EIC, early invasive cancer

Supplementary Table 2. Clinical findings for each tumor type in the validation set

		HP n=18	SSL n=25	SSLD/SSL with EIC n=4	TSA n=23	TSA with cancer n=3
Age (y, mean ± SD)		67.3 ± 10.3	67.7 ± 9.2	79.0 ± 7.5	66.4 ± 11.2	53.7 ± 13.5
Gender	Female	5	12	3	12	1
	Male	13	13	1	11	2
Location	Proximal	11	23	4	5	0
	Distal	7	2	0	18	3
Size (mm, mean ± SD)		7.6 ± 3.7	13.8 ± 6.3	14.5 ± 5.3	8.4 ± 3.6	24.0 ± 18.2
Morphology	Flat	14	21	1	0	1
	Flat plus protoruding	1	2	2	13	0
	Protoruding	3	2	1	10	2

SSLD, SSL with dysplasia; EIC: early invasive cancer